Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

This publication has 43 references indexed in Scilit:

• MONITORED HIGH-DOSE AZATHIOPRINE TREATMENT REDUCES ACUTE REJECTION EPISODES AFTER RENAL TRANSPLANTATION
  Transplantation, 1998
• Toxicities and infections associated with chronic 6-Mercaptopurine (6-MP) use in Crohn's disease (CD): do we need to discontinue treatment?
  Gastroenterology, 1998
• Nuclear DNA diversity in worldwide distributed human populations
  Gene, 1997
• Should 6- Thioguanine Nucleotides Be Monitored in Heart Transplant Recipients Given Azathioprine?
  Therapeutic Drug Monitoring, 1996
• Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy
  Canadian Journal of Physiology and Pharmacology, 1996
• Clinical classification of perianal Crohn's disease
  Diseases of the Colon & Rectum, 1992
• Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
  The Journal of Pediatrics, 1991
• Favorable effect of 6-Mercaptopurine on fistulae of Crohn's disease
  Digestive Diseases and Sciences, 1985
• Variable Bioavailability of Oral Mercaptopurine
  New England Journal of Medicine, 1983
• Treatment of Crohn's Disease with 6-Mercaptopurine
  New England Journal of Medicine, 1980